There are little data on the impact of antiretroviral therapy (ART) regimen factors on adherence in ART na?ve HIV patients on contemporary once or twice daily regimens. HAART consisted of complicated regimens with high pill burden and frequent dosing. Newer regimens consist of fixed-dose combination pills. In October 2004, the Department of Health and Human Services treatment guidelines recommended use of efavirenz (EFV) with emtricitabine (FTC) and tenofovir (TDF) in HIV-treatment na?ve patients as one of the preferred regimens.1 Thereafter, a fixed dose combination one-pill, once-daily regimen of EFV/FTC/TDF was developed. Several Ostarine studies have shown that characteristics of antiretroviral regimens can affect patients medication adherence. A recent meta-analysis of 11 randomized, controlled trials of different HAART regimens found that adherence was higher with once-daily regimens (+2.9%; 95% confidence interval 1.0%C4.8%; p<0.003) than twice-daily regimens, with a more profound effect seen at the time of treatment initiation.2 Fixed dose combination EFV/FTC/TDF was not studied in comparison to other once-daily regimens in that meta-analysis. Participants Ostarine in a prospective cohort study had higher adherence on HAART with low dosing frequencies (the lowest being twice daily) but not with low pill burden.3 A 5-month observational cohort study of participants who had been on HAART for more than four months found that a lower number of pills (p= 0.02) and fewer daily doses (p=0.02) were associated with higher adherence as measured by the Adult AIDS Clinical Ostarine Trial Group (AACTG) 4-day self-report instrument.4 In addition, a prospective observational study in Italy found higher AACTG 4-day self-report adherence for participants with a lower number of pills in their prescribed HAART regimen (p=0.02) and a lower number of required daily doses (p=0.04).5 Fixed dose combination EFV/FTC/TDF was not available in the latter three studies. Bangsberg et al. recently conducted a prospective observational cohort study in primarily HAART-experienced homeless participants for six months and found that adherence by unannounced pill count was higher in participants who took fixed dose combination EFV/FTC/TDF compared to participants taking any other regimen (p<0.01).6 Airoldi et al. found that patients who were first treated with FTC + TDF + EFV or Ostarine lamivudine (3TC) + TDF + EFV and had a HIV-RNA <50 copies/mL and were then switched to fixed-dose combination EFV/FTC/TDF had better adherence after the switch (93.8% vs. 96.1%, respectively, p<0.01).7 These studies, including the studies in the meta-analysis, did Ostarine not assess adherence to contemporary HAART regimens (including fixed Rabbit Polyclonal to VEGFR1 (phospho-Tyr1048). dose combination EFV/FTC/TDF) in newly diagnosed, HAART-na?ve patients. Whether a one-pill once-daily regimen promotes higher adherence than other once daily regimens in HAART-naive patients is unknown. We report the adherence to contemporary HAART regimens of newly diagnosed, HAART-na?ve participants in an 18-month prospective cohort study. Patients and Methods Study Design, Participants & Setting We conducted a prospective, observational cohort study of patients newly diagnosed with HIV infection in Houston, TX. Details of screening and enrollment into the Attitudes and Beliefs and the Steps of HIV Care study (the Steps Study) are outlined by Bhatia, et al.8 Participants completed an interviewer-administered questionnaire at baseline and every three months for up to 18 months. These questionnaires were generally completed outside of the clinical setting. The questionnaires included items on demographics, HIV risk factors, and incarceration history, as well as a visual analogue scale (VAS) adherence measure for each of their HIV medications if they had been prescribed them.9 Participants did not undergo standardized adherence counseling as part of the research protocol. Most patients starting HAART in the clinic receive adherence counseling as part of routine care from their provider and either a nurse adherence counselor or a clinical pharmacist. Laboratory data from routine care were retrieved, and medical records were reviewed to verify participants HAART regimens. Outcome Measures and Data Analysis For 30-day VAS adherence, the location of the X that the participant wrote on the response scale was converted to a percent. For example, if they placed an X at the 50% mark on the scale for a medication, their adherence for that medication would be recorded as 50%.9 The mean adherence for all of the HIV medications in a participants regimen was calculated at each study time point. The median adherence.